

Curriculum Vitae

INFORMAZIONI PERSONALI

Giovanna Paolone

📍 Dipartimento di Diagnostica e Sanità Pubblica, Sezione di Farmacologia
P.le Scuro 10, 37134 Verona (VR)

☎ +39 045 802 7224 (office)

✉ giovanna.paolone@univr.it

30 novembre 2019 ad
oggi

Ricercatore a tempo determinato *Senior* (RTD-B), Settore Scientifico Disciplinare:
BIO/14 - Farmacologia, presso la Sezione di Farmacologia - Dipartimento di
Diagnostica e Sanità Pubblica,
Università degli Studi di Verona

giugno 2018-
29 novembre 2019

Ricercatore a tempo determinato *Junior* (RTD-A), Settore Scientifico Disciplinare:
BIO/14 - Farmacologia, presso la Sezione di Farmacologia - Dipartimento di
Diagnostica e Sanità Pubblica,
Università degli Studi di Verona

2017

Assegno di ricerca
Titolo del progetto: Caratterizzazione in silico e in vitro del recettore orfano 3
accoppiato alla proteina G (GPR3),
Responsabile scientifico: Prof. Alejandro Giorgetti e Prof. Mario Buffelli
Presso la sezione di Fisiologia - Dipartimento di Neuroscienze, Biomedicina e Scienze
del Movimento,
Università degli Studi di Verona

2015-2017

Assegno di ricerca
Titolo del progetto: Identificazione di biomarcatori di epilessia in modelli
sperimentali.
Progetto Europeo EPITARGET (FP7-HEALTH project 602102)
Responsabile scientifico: Prof. Michele Simonato
Presso la sezione di Farmacologia - Dipartimento di Scienze Mediche,
Università degli Studi di Ferrara

2015
(aprile-ottobre)

Marie Curie Industry Fellow – Industry Academia Partnerships and Pathways.
Progetto Europeo EPIXCHANGE (FP7-PEOPLE-2011-IAPP 536 project
285827)
Gloriana Therapeutics *Inc.* (Former NsGene), Providence, RI, USA

2013-2015

Assegno di ricerca
Titolo del progetto: Discinesia indotta dalla L-DOPA nella malattia di
Parkinson: nuovi meccanismi e targets molecolari.
Responsabile scientifico: Prof. Michele Morari
Presso la sezione di Farmacologia - Dipartimento di Scienze Mediche,
Università degli Studi di Ferrara

- 2013
(marzo-settembre) Ricercatore a Tempo Determinato (ex Art. 23 del D.P.R. 12 febbraio 1991 n. 171)
Istituto di Genetica e Biofisica "A. Buzzati Traverso"
Consiglio Nazionale delle Ricerche (CNR), Napoli
- 2010 – 2013 Assistant Research Scientist
Prof. Martin Sarter
University of Michigan, Ann Arbor, MI, United States
- 2008 – 2010 Post Doctoral Fellow
Prof. Dr. Theresa Lee and Prof. Martin Sarter
University of Michigan, Ann Arbor, MI, United States
- 2006 – 2008 Post Doctoral Fellow
Prof. Jane Stewart
Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC,
Canada
- 2003
(febbraio-maggio) Research Scientist
Prof. Jane Stewart
Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC,
Canada

ISTRUZIONE E FORMAZIONE

- 2014 ***Abilitazione Scientifica Nazionale*** alle finzioni di Professore Universitario di
Seconda Fascia, Settore Concorsuale 11/E1 - Settore Scientifico Disciplinare:
Psicologia Generale, Psicobiologia e Psicomatria - M-PSI/01, M-PSI/02, M-
PSI/03 - (Decreto Direttoriale n.222 del 20 luglio 2012) conseguita a febbraio
2014.
- 2005 Dottore di Ricerca in Farmacologia (XVII ciclo)
Titolo: "Modulazione ambientale degli effetti neurocomportamentali dei
farmaci psicostimolanti e oppioidi"
Sapienza, Università degli Studi di Roma
- 2001 Laurea in Psicologia Indirizzo Generale e Sperimentale (108/110),
Tesi sperimentale con titolo "Modulazione ambientale degli effetti analgesici
della morfina".
Sapienza, Università degli Studi di Roma

ATTIVITA' DIDATTICA

- A.A. 2018-2019 Docente di Farmacologia - modulo di Farmacologia Generale - titolare Prof.
Cristiano Chiamulera, Laurea in Tecniche di Laboratorio Biomedico,
Università degli Studi di Verona

ATTIVITA' TUTORIALE E DI COORDINAMENTO

- 2006-2018 Tutor/Relatore
Corso di Laurea Triennale in Biopsicologia e Neuroscienze, n=3
Corso di Laurea Magistrale in Biopsicologia e Neuroscienze, n=2
CSBN, Concordia University, Montreal (QC), Canada
- 2008-2013 Tutor/Relatore
Corso di Laurea Triennale in Biopsicologia e Neuroscienze, n=8
Corso di Laurea Magistrale in Biopsicologia e Neuroscienze, n=4
Co-Relatore di studenti iscritti al Dottorato di Ricerca in Neuroscienze, n=2
Co-Supervisore di studenti di post-dottorato, n=3
University of Michigan, Ann Arbor, MI, USA
- A.A.2013-2014 Correlatrice
Corso di laurea in Farmacia
Titolo: Meccanismi neurochimici e molecolari alla base degli effetti antidiscinetici di eltoprazina
Università degli Studi di Ferrara
- A.A.2013-2014 Correlatrice
Titolo: Eltoprazina nel trattamento delle discinesie indotte da L-DOPA
Corso di laurea in Farmacia
Università degli Studi di Ferrara
- A.A.2015-2016 Secondo Relatore
Corso di Laurea in Chimica e Tecnologia Farmaceutiche
Titolo: Cellule incapsulate per il rilascio localizzato di GDNF: un nuovo approccio terapeutico per il trattamento dell'epilessia?
Università degli Studi di Ferrara
- A.A.2017-2018 Tutor
Corso di Laurea Triennale in Biotecnologie
Titolo: Effects of glucocorticoids on spine plasticity and inflammation in an animal model of Alzheimer Disease
Università degli Studi di Verona
- A.A.2019-2020 Relatore
Corso di Laurea Triennale in Biotecnologie
Titolo: Monitoring effects of progranulin secretion from encapsulated cells implanted in rat striatum
Università degli Studi di Verona

Il candidato è risultato vincitore di una borsa di studio nell'ambito del programma europeo *Erasmus Plus* per un soggiorno presso l'azienda **Sinfonia Biotherapeutics**, AB locata a Stoccolma, Svezia (gennaio-giugno

2020)

CONSEGUIMENTO DI PREMI E RICONOSCIMENTI SCIENTIFICI

- 2019 Cittadino d'eccellenza per l'anno 2019 conferito dal Sindaco della Città di Verona per "la dedizione e i successi che hanno contribuito ad aggiungere prestigio alla nostra Città"
Verona, VR, Italia, 9 gennaio 2020
- 2018 Scientist Medal for outstanding research in the field of "*New Age Technology and Innovations*", conferito da International Association of Advanced Material.
Stockholm, Sweden Oct 9-12
- 2007 Travel Bursary to attend the Biennial European Behavioral Pharmacology Society Meeting
Tübingen, Germany, Aug 31-Sept 03
- 2006 Borse di Studio per soggiorno di studio all'estero conferito da Società Italiana di Farmacologia (SIF)
- 2005 Travel Bursary to attend the Biennial European Behavioral Pharmacology Society Meeting
Barcelona, Spain, Sept 09-12 2005
- 2003 Borse di Studio per soggiorno di studio all'estero conferito da Società Italiana di Farmacologia (SIF), anno 2003.
- 2001 Borse di studio di eccellenza conferito da Sapienza, Università degli Studi di Roma.
- 2000 Borse di studio di eccellenza conferito da Sapienza, Università degli Studi di Roma.

ATTIVITA' DI RICERCA- RESPONSABILITA' SCIENTIFICA PER PROGETTI DI RICERCA

- 2020 Responsabile Scientifico (PI), **Bando di Ateneo per la Ricerca di Base**; durata 24 mesi
Titolo: From the gut to the brain and back: novel therapeutic approaches for the treatment of Parkinson disease as network dysfunction.
Collaboratori:
Prof Matteo Brunelli, Anatomia Patologica, Università di Verona
Prof Michele Tinazzi, Neurologia, Università di Verona
Gloriana Inc., Providence, RI, USA
- 2020 Responsabile Scientifico (Principal Investigator, PI), progetto internazionale finanziato da **Sinfonia Biotherapeutics, AB**, Huddinge, Sweden;

Titolo: neuroprotective effects of progranulin, prosaposin, GDNF and combinations thereof in a rat 6-OHDA model of Parkinson's disease.

- 2019 Responsabile Scientifico (Principal Investigator, PI), progetto internazionale finanziato da finanziato da **Sinfonia Biotherapeutics**, AB, Huddinge, Sweden;
Titolo: Long-term progranulin secretion from devices implanted into rat Striatum.
- 2019 Responsabile Scientifico (PI), progetto internazionale finanziato da **FUR FURDIPDSP_ASS_FARMA**; durata 12 mesi
Titolo: Effetti della terapia basata su cellule umane incapsulate e ingegnerizzate per il rilascio di GDNF su modelli animali di malattia di Parkinson.
- 2019 Responsabile Scientifico (PI), Progetto finanziato da **Brain Research Foundation Verona**; durata 12 mesi
Titolo: Trattamento della malattia di Parkinson in un modello di ratto che esprime α -sinucleina umana con cellule umane incapsulate e ingegnerizzate per il rilascio di GDNF.
- 2019 Co-Responsabile Scientifico (Co-PI), Progetto finanziato da **Zardi-Gori Foundation**; durata 12 mesi,
Titolo: A novel therapeutic approach for dopamine agonists medication-induced Disorders.

PRINCIPALI COLLABORAZIONI SCIENTIFICHE

Gloriana, Inc., Providence, RI, USA – Brain Repair Device –
Sinfonia Biotherapeutics, AB, Huddinge, Sweden
Dipartimento di Scienze Mediche,
Università di Ferrara, FE, Italia
Dipartimento of Neuroscienze, Biomedicina and Movimento,
Dipartimento di Diagnostica e Sanità Pubblica,
Università di Verona, VR, Italia.

CAPACITÀ E COMPETENZE PROFESSIONALI

Gli interessi scientifici, le competenze acquisite e l'attività di ricerca e che ho svolto nel corso degli anni, sono principalmente focalizzati sulla farmacologia del sistema nervoso centrale.

Ho iniziato esplorando la modulazione ambientale sulla risposta ai farmaci d'abuso per poi investigare come la manipolazione farmacologia moduli gli effetti dei farmaci psicostimolanti.

Negli ultimi anni, i miei studi riguardano principalmente gli effetti di una terapia innovativa basata su cellule ingegnerizzate per rilasciare agenti terapeutici e incapsulate applicata a modelli sperimentali di malattie

neurologiche e degenerative.

2020 Adesione al collegio docenti del corso di dottorato in Neuroscienze, Scienze Psicologiche e Psichiatriche e Scienze del Movimento, Università degli Studi di Verona

ATTIVITA' DI REVIEWER

2020 Reviewer di progetti di ricerca sottoposti a richiesta di finanziamento al programma *Synergy* - European Research Council

ATTIVITÀ DI PEER REVIEWER

Per le seguenti Riviste Scientifiche Internazionali:

Molecular Neurobiology
Neurobiology of Disease
Psychopharmacology
Cytotherapy
Experimental Neurology

AFFILIAZIONE A SOCIETA' SCIENTIFICHE

Società Italiana di Farmacologia (SIF)
Società Italiana di Neuroscienze (SINS)
Federazione Italiana Epilessia (FIE)
Society for Neuroscience (SfN)
European Behavioral Pharmacology Society (SfN)
The International College of Neuropsychopharmacology (CINP)

Capitoli e monografie

1- Falcicchia C, **Paolone G**, Simonato M
Cell Therapy for Epilepsy
in *Cell Therapy: Current Status and Future Directions* (DF Emerich., & G. Orive Eds.), Springer International Publishing, New York, NY, USA 2017.

Pubblicazioni su Riviste Scientifiche Internazionali

1. **Paolone G**, Burdino R, Badiani A. (2003) Dissociation in the modulatory effects of environmental novelty on the locomotor, analgesic, and eating response to acute and repeated morphine in the rat. *Psychopharmacology* 166:146-155.
2. Antonilli L, Suriano C, **Paolone G**, Badiani A, Nencini P. (2003) Repeated exposures to heroin and/or cadmium alter the rate of formation of morphine glucuronides in the rat. *J Pharmacol Exp Ther* 307: 651-660.

- 3. Paolone G**, Paolopoli M, Marrone MC, Nencini P, Badiani A. (2004) Environmental modulation of the interoceptive effects of amphetamine in the rat. *Behav Brain Res* 152:149-155.
- 4. Scaccianoce S**, Del Bianco P, **Paolone G**, Caprioli D, Modafferi AM, Nencini P, Badiani A. (2006) Social isolation selectively reduces hippocampal brain-derived neurotrophic factor without altering plasma corticosterone. *Behav Brain Res* 168: 323-325.
- 5. Botreau F**, **Paolone G**, Stewart J. (2006) d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. *Behav Brain Res* 172:173-178.
- 6. Caprioli D**, **Paolone G**, Celentano M, Testa A, Nencini P, Badiani A. (2007) Environmental modulation of cocaine self-administration in the rat. *Psychopharmacology* 192:397-406.
- 7. Paolone G**, Conversi D, Caprioli D, Del Bianco PD, Nencini P, Cabib S, Badiani A. (2007) Modulatory effect of environmental context and drug history on heroin-induced psychomotor activity and fos protein expression in the rat brain. *Neuropsychopharmacology* 32:611-623.
- 8. Caprioli D**, Celentano M, **Paolone G**, Badiani A. (2007) Modeling the role of environment in addiction. *Prog Neuropsychopharmacol. Biol Psychiatry* 31:1639-653.
- 9. Caprioli D**, Celentano M, **Paolone G**, Lucantonio F, Bari A, Nencini P, Badiani A. (2008) Opposite environmental regulation of heroin and amphetamine self-administration in the rat. *Psychopharmacology* 198:395-404.
- 10. Paolone G**, Botreau F, Stewart J. (2009) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced conditioned place preference can be long lasting and resistant to reinstatement. *Psychopharmacology* 202:403-409.
- 11. Sarter M & Paolone G**, (2011) Deficits in attentional control: cholinergic mechanisms and circuits-based treatment approaches. *Behavioral Neurosci. Dec*; 125(6):825-835.
- 12. Paolone G**, Lee TM, Sarter M. (2012) Time to pay attention: attentional performance time-stamped prefrontal cholinergic activation, diurnality and performance. *J. Neurosci. Aug* 2012, 32(35): 12115-128.
- 13. Paolone G**, Angelakos CC, Meyer PJ, Robinson TE, Sarter M. (2013) Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. *J. Neurosci.* 33(19): 8321-335.

- 14. Paolone G**, Mallory C, Koshy Cherian A, Sarter M. (2013) Monitoring cholinergic activity during attentional performance in mice heterozygous for the choline transporter: a model of cholinergic capacity limits. *Neuropharmacology*, 16; 75C:274-285.
- 15. Kucinski A, Paolone G**, Bradshaw M, Albin RL, Sarter M. (2013) Attention, movement control, and fall propensity: Analysis of multi-system model of Parkinson`s Disease using a novel behavioral test system for the assessment of deficits in the cognitive control of gait, balance and complex movement in rats. *J. Neurosci.* 33(42): 16522-539.
- 16. Grupe M, Paolone G**, Jensen AA, Sandager-Nielsen K, Sarter M, Grunnet M. (2013) Selective potentiation of $(\alpha 4)_3(\beta 2)_2$ nicotinic acetylcholine receptors augments amplitudes of prefrontal nicotine-evoked glutamatergic transients in rats. *Biochem Pharmacol.* 86(10): 1487-496.
- 17. Cristino L, Luongo L, Squillace M, Paolone G**, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, Nisticò R[@], Usiello A[@]. (2015) d-Aspartate oxidase, influences glutamatergic system homeostasis in mammalian brain. *Neurobiol Aging* 15: 1-13.
- 18. Paolone G**, Brugnoli A, Arcuri A, Daniela Mercatelli and Morari M. (2015) Eltoprazine prevents dyskinesias by reducing striatal glutamate and direct pathway neuron activity. *Movement Disorders* 30(13): 1728-738
- 19. Sacchi S, De Novellis V, Paolone G**, Nuzzo T, Iannotta M, Belardo C, Squillace M, Bolognesi P, Rosini E, Motta Z, Frassinetti M, Bertolino A, Pollegioni L, Morari M, Maione A, Errico F, Usiello A. (2017). Olanzapine but not clozapine increases glutamate release in the pre-frontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. *Scientific Report* 7:46288.
- 20. Paolone G**, Falcicchia C, Verlengia G, Barbieri M, Binaschi A, Paliotto F, Paradiso B, Soukupova M, Zucchini S, Simonato M. (2018) A refined technique for microinjections in the rodent brain. *J Vis Exp.* 24;131.
- 21. Falcicchia C. Paolone G**, Emerich DF, Lovisari F, Bell W, Fradet T, Wahlberg LU, Simonato M. (2018) Seizure-Suppressant and Neuroprotective Effects of Encapsulated BDNF-Producing Cells in a Rat Model of Temporal Lobe Epilepsy. *Molecular Therapy – Methods and Clinical Development.* *Mol Ther Methods Clin Dev.* 9;9:211-224.
- 22. Paolone G**, Falcicchia C, Lovisari F, Kokaia M, Bell W, Fradet T, Wahlberg LU, Emerich DF, Simonato M. (2019) Long-term, targeted delivery of GDNF from

encapsulated cells is neuroprotective and reduces seizures in the pilocarpine model of epilepsy.

J Neurosci. 13;39(11):2144-156

23. Emerich DF, Kordower JH, Chu Y, Thanos C, Bintz B, **Paolone G**, and Wahlberg LU. (2019) Widespread striatal delivery of gdnf from encapsulated cells prevents the anatomical and functional consequences of excitotoxicity. *Neural Plast.* 11;2019:6286197.

24. Piva A, Gerace E, Di Chio M, Padovani L, **Paolone G**, Pellegrini-Giampietro DE, Chiamulera C. (2019) Reconsolidation of sucrose instrumental memory in rats: the role of retrieval context. *Brain Res.* 1714:193-201.

25. Pedrazzoli M, Losurdo M, **Paolone G**, Avesani A, Coco S, Buffelli M. (2019) Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's Disease. *Neurobiology of Disease* Aug 5;132:104568.

26. Orive G, Echave MC, Dolatshahi-Pirouz A, **Paolone G**, Emerich DF. (2019) Advances in Cell-laden Hydrogels for Delivering Therapeutics. *Expert Opinion on Biological Therapy* Expert Opin Biol Ther. 2019 Aug 26:1-4

27. Piva A, Caffino L, Padovani L, Pintori N, Mottarlini F, Sferrazza G, **Paolone G**, Fumagalli F, Chiamulera C. (2019) The metaplastic effects of ketamine on renewal and reconsolidation of sucrose contextual memory in rats. *Brain Res* 2020 Feb 379:112347.

28. **Paolone G**, Wahlberg LU, Policastro G, and Emerich DF. (2020) Encapsulated cell therapy for the treatment of epilepsy. (*In press: Current Neurobiology*).

29. Wahlberg LU, Emerich DF, Kordower JH, Bell W, Fradet T, **Paolone G**. (2020) Long-term, stable, targeted biodelivery and efficacy of GDNF from encapsulated cells in the rat and Goettingen miniature pig brain. (*in press: Current Research in Pharmacology and Drug Discovery*).

30. Dolatshahi-Pirouz A, Ostrovidov S, **Paolone G**, Peppas N, de Vos P, Emerich DF, Orive G. (2020) Cell-laden alginate hydrogels: the progress of living medicines for drug delivery (*in press: Expert Opinion in Drug delivery*).

31. Lovisari F,* Roncon P,* Soukoupova M, **Paolone G**, Labasque M, Ingusci S, Falcicchia C, Johnson M, Rossetti T, Petretto E, Leclercq K, Kaminski RM, Moyon B, Webster Z, Michele Simonato M** and Zucchini S**. (2019). Implication of Sestrin3 in epilepsy and its comorbidities.

(Submitted).

Comunicazioni/abstract a convegni/congressi nazionali/internazionali

Relatore su invito a
convegni/
congressi

Paolone G.

Encapsulated cell therapy: targeting dopaminergic and cholinergic structural alterations with GDNF as a new strategy in the pathophysiology of neurodegenerative disorders. *Biennial Meeting of the European Behavioural Pharmacology Society*. Braga-Porto, Portugal, August 28-31 2019. Abstract book.

Paolone G. - Marie Skłodowska Curie Action final presentation – FP7 MC-IAPP –

Long-term delivery of GDNF by encapsulated cells for the treatment of epilepsy. In *“Epilepsy research in the EU: state of the art and opportunities for the future”* Ferrara, October 28, 2015.

Paolone G.

Encapsulated cell therapy for epilepsy: long-term, stable, and efficacious targeting of the hippocampus with GDNF. *International Association of Advanced Materials Conference*. Stockholm, Sweden. October 9-12, 2018. Abstract Book.

Paolone G.

GDNF: the old and the newest as promising approach for the treatment of epileps. *Temporal Lobe Epilepsy: a window on the brain*, presso IRCCS-NeuroMed, Pozzilli (IS), Italy. May 16-17, 2019.

Paolone G.

Delivery GDNF from encapsulated cells: the old and the newest as promising approach for the treatment of neurological and degenerative diseases. *International Conference on Alzheimer's and Dementia*. Dubai, UAE September 23-25, 2019.

Seminari su invito

Paolone G.

Environmental modulation of psychomotor, subjective, and reinforcing effects of addictive drugs. Presso Douglas Hospital Research Center, Neuroscience Division - McGill University, Montreal (QC), Canada. December 2006.

Paolone G.

Conditioning and self-administration of psychostimulants and opiate drugs. Evidences on Neurodegeneration, Plasticity and Repair. Neurofortis, Lund University; Lund, Sweden, September 2007

Paolone G.

Conditioning, self administration and extinction of psychostimulants and opiate drugs. Department of Psychology, University of Michigan; Ann Arbor, MI, USA. October 2007

Paolone G.

Prior daily practice on a sustained attention task synchronizes the increase of prefrontal ACh release and desynchronizes peripheral oscillators.

Department of Psychology, Michigan State University, Lansing, MI, USA. August 2010

Paolone G.

Staying cognitively engaged during the wrong time of the day: cognitive cholinergic induction of diurnality and reorganization of multiple circadian rhythms.

Department of Psychology, University of Michigan; Ann Arbor, MI, USA. April 2012

Paolone G.

Prefrontal cholinergic neurotransmission under attentional and pharmacological manipulation in CHT $+/+$ and CHT $+/-$

Department of Psychology, University of Michigan; Ann Arbor, MI, USA. May 2012

Paolone G.

Highly demanding cognitive task and optical stimulation of cholinergic system: old and new approaches to explore mechanisms of attention in rats and mice.

Institute of Genetics and Biophysics “A. Buzzati-Traverso”

Consiglio Nazionale delle Ricerche (CNR); Naples, Italy. March 2013

Paolone G.

Reward, Cognition and GDNF: where we are and where we would like to go.

Italian Institute of Neuroscience, Section of Verona.– Open neuroscience forum. Verona, Italy. November 2017.

Paolone G.

Reward, Cognition, and Encapsulated Cell Therapy with GDNF: “state of the art” and future directions.

University of Verona, Department of Diagnostic and Public Health, Verona, Italy.

May 2018.

Paolone G.

FROM the neurobiology of rewards TO innovative therapeutic approaches for neurological and degenerative disorders.

University of Verona, Department of Diagnostic and Public Health, Verona, Italy.

November 2019.

Paolone G.

From the gut to the brain and back: novel therapeutic approaches for the treatment of Parkinson’s disease.

The University of Sussex, School of Psychology, Brighton, United Kingdom.

September 2020.

Molecules in Neuroscience (Y. Michotte, Westerink, B., & S. Sarre Eds.), Printer TBD, Brussels, 2010.

Sarter M, Parikh V, Howe MW, Gritton H, **Paolone G**, Lee TM. (2010) Multiple time scales and variable spaces: synaptic neurotransmission *in vivo*. In *Monitoring Molecules in Neuroscience* (Y. Michotte, Westerink, B., & S. Sarre Eds.), Printer TBD, Brussels, 2010.

Sarter M, **Paolone G**, Mabrouk OS, Kennedy RT. (2012) Sampling from injured tissue as a blessing in disguise: tonic changes in cholinergic neurotransmission using microdialysis. In *Monitoring Molecules in Neuroscience* (Y. Michotte, Westerink, B., & S. Sarre Eds.) Printer TBD, London, UK.

Brusini L, Cruciani F, Boscolo Galazzo I, Galbusera A, Borin M, **Paolone G**, Diana G, Buffelli M, Gozzi A, Menegaz G. (2019) Can single shell diffusion mri detect synaptic plasticity in mice? In *IEEE International symposium on biochemical imaging 2019* (ISBN 978-1-5386-3641-1).

Presentazioni a
conferenze
(abstract)

Paolone G, Badiani A (2001) Environmental novelty enhances the locomotor activating but not the analgesic effects of morphine. *Pharmacological Research*, 43 (suppl A):156

Paolone G, Burdino R, Badiani A (2001) Environmental novelty differentially modulates the locomotor activating versus the analgesic effects of acute and repeated morphine. *Society for Neuroscience*. Abstract 26

Paolone G, Palopoli M, Nencini P, Badiani A (2003) Environmental modulation of amphetamine discrimination in the rat. *Behavioural Pharmacology*, 14 (suppl 1): S58

Paolone G, Palopoli M, Nencini P, Badiani A (2003) Environmental novelty facilitates amphetamine discrimination in the rat. *Society for Neuroscience*. Abstract 643.15

Stewart J, Sorge RE, Leri F, **Paolone G**, (2003) The opioid agonist-antagonist, buprenorphine, preferentially suppresses cocaine self-administration over heroin in rats trained to self-administer both drugs. *Society for Neuroscience*. Abstract 109.

Leri F, Tremblay A, Sorge RE, **Paolone G**, Goddard B, Stewart J (2003) Effects of methadone maintenance on cocaine-motivated behaviour. *Society for Neuroscience*. Abstract 109.16

Sorge RE, Jenkins PA, **Paolone G**, Stewart J (2003) Effects of amount of exposure to cocaine self-administration and time since termination of drug taking on relapse to drug seeking assessed in extinction and follow acute foot-shock stress. *Society for Neuroscience*. Abstract 421.

Antonilli L, **Paolone G**, Badiani A, Nencini P (2003) Repeated exposures to heroin and/or cadmium alter the rate of morphine glucuronides in the rat. *Society for Neuroscience*. Abstract 645.6

Paolone G, Caprioli D, Palopoli M, Nencini P and Badiani A (2004) Environmental modulation of the interoceptive effects of cocaine and morphine. EBPS, Rome, Sept 2-4. *Behavioural Pharmacology*, (volume 15, num 5&6).

Paolone G, Caprioli D, Celentano M, Badiani A (2006) Environmental modulation of cocaine self-administration. *Society for Neuroscience*. Abstract 590.2

Caprioli D, Celentano M, **Paolone G**, Testa A, Badiani A (2006) Environmental modulation of heroin self-administration. *Society for Neuroscience*. Abstract 590.3

Paolone G, Hood S, Stewart J (2007) Effect of inter-trial-interval and duration of exposure on the facilitation of extinction of a cocaine-induced conditioned place preference by d-cycloserine. *Society for Neuroscience*. Abstract 638.2.

Paolone G, Benatar A, Stewart J (2007) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced Conditioned Place Preference can be long lasting and resistant to reinstatement: effects of extinction variables. *Canadian Association for Neuroscience*.

Paolone G, Benatar A, Stewart J (2007) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced Conditioned Place Preference can be long lasting and resistant to reinstatement: effects of extinction variables. *Canadian College of Neuropsychopharmacology*.

Paolone G, Hood S, Stewart J (2007) The facilitative effects of D-Cycloserine on extinction of a cocaine-induced Conditioned Place Preference and Fos Protein Expression in the Pre-Frontal Cortex. *European Behavioral Pharmacology Society*.

Paolone G, Ismail N, Pfaus J, Badiani A, Stewart J. (2008) An established preference for a conditioned stimulus associated with either sucrose or copulation in male rats subsequently shifts to a preference for a conditioned stimulus paired with cocaine self-administration. *Society for Neuroscience*. Abstract 687.

Paolone G, Ji J, Williams S, Howe WM, Ward J, Decker MW, Parikh V, Sarter M. (2009) Effects of the selective alpha 7 nAChR agonist ABT-107 on prefrontal glutamatergic and cholinergic activity and attentional performance. *Society for Neuroscience*. Abstract 227.

Lee TM, **Paolone G**, Gritton H, Yan J, Hoogerwerf W, Sarter M. (2010) Timed, sustained, attention-demanding performance reorganizes or dampens multiple circadian rhythms. *Society for Research in Biological Rhythms*.

Paolone G, Howe WM, Decker MW, Gopalarishnan, Sarter M. (2010) Multiple modes of cholinergic neurotransmission - Multiple functions. *Society for*

Neuroscience. Abstract 703.

Lee TM, **Paolone G**, Howe WM, Sarter M. (2010) Staying cognitively engaged during the wrong time of the day: cognitive-cholinergic induction and maintenance of diurnality in rats. *Society for Neuroscience*. Abstract 98.

Gritton H, Howe WM, Hetrick VL, **Paolone G**, Berke JD, Sarter M. (2010) Optogenetically-evoked cortical cholinergic transients in mice expressing channelrhodopsin-2 (ChR2) in cholinergic neurons. *Society for Neuroscience*. Abstract 304.

Yan J, **Paolone G**, Bostowick J, Hoogerwerf W, Sarter M, Lee TM. (2010) Daily performance of a sustained attention task during light phase desynchronizes circadian oscillators in nocturnal rats. *Society for Neuroscience*. Abstract 499.

Sarter M, Howe WM, **Paolone G** (2011). Real-time biosensing of glutamatergic and cholinergic neurotransmission in vivo: implications for psychopharmacology. *Summer meeting of the British Association for Psychopharmacology*. J. of Psychopharmacology. Aug 2011, 25(8): A6-A6.

Angelakos CC, **Paolone G**, Meyer PJ, Robinson TE, Sarter M. (2011) Sign- versus goal trackers, top down control of attention, and underlying cholinergic mechanisms. *Society for Neuroscience*. Abstract 197.

Paolone G, Spuz CA, Brisco S, Bradshaw M, Albin RL, Sarter M. (2011) Deficits in attentional control of balance, mobility, and complex movements in a rat model of early state, multisystem Parkinson disease. *Society for Neuroscience*. Abstract 244.

Paolone G, Lamy D, Sarter M, Lee TM. (2011) Cognitive performance-associated increases in cholinergic neurotransmission also serve as a circadian signal to sustain performance-induced diurnal activity pattern. *Society for Neuroscience*. Abstract 610.

Paolone G, Angelakos CC, Meyer PJ, Robinson TE, Sarter M. (2011) Poor and Unstable Sustained Attentional Performance in Sign-Trackers: An Animal Model of Poor Top Down Cognitive Control of Attention. American College of Neuropsychopharmacology Annual Meeting, December 4-8, HI.

Sarter M, Howe MW, **Paolone G**, (2011) Real time biosensing of glutamatergic and cholinergic neurotransmission in vivo: implications for psychopharmacology. In: *Journal of Psychopharmacology*. Vol. 25.

Paolone G, Mabrouk OS, Kennedy RT, Sarter M. (2012) High temporal resolution microdialysis reveals cholinergic spikes preceding upshifts in attentional performance. *Society for Neuroscience 2012* - **Abstract selected for nanosymposium**.

Mallory C, **Paolone G**, Cherian Koshy A, Blakely RD, Sarter M. (2012) Paying attention with a compromised cholinergic system: attenuated activation of cholinergic neurotransmission in attentional task-performing CHT+/- mice. *Society for Neuroscience*. Abstract 599.

Grube M, **Paolone G**, Jensen AA, Nielsen KS, Christensen JK, Grunnet M, Sarter M. (2012). Positive allosteric modulation of $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors augments the amplitudes of prefrontal nicotine-evoked glutamatergic transients. *Society for Neuroscience*. Abstract 365.

Kucinsky A, **Paolone G**, Peterson CC, Ronan EA, Albin RL, Sarter M. (2012). Deficits in the attentional control of posture and complex movements in a rat model of early state, multisystem Parkinson's disease. *Society for Neuroscience*. Abstract 259.

Paolone G, Arcuri A, Brugnoli A, and Morari M (2014). Eltoprazine attenuates L-DOPA induced dyskinesia along with GABA and Glutamate release in rat substantia nigra. *Federation of European Neuroscience Societies*; Milan, Italy.

Paolone G, Tornoe J, Bell W, Fradet T, Emerich DF, Wahlberg LU (2015). Encapsulated cell therapy for Parkinson's disease: long-term, stable and efficacious targeting of the nigrostriatal dopaminergic system with GDNF. *Gordon Research Conference, Catecholamines*. Sunday River, ME, USA.

Falcicchia C, **Paolone G**, Emerich DF, Bell W, Fradet T, Wahlberg LU, Simonato M (2016). Seizures-suppressant effect of encapsulated BDNF-producing cells in a rat model of temporal lobe epilepsy. *Federation of European Neuroscience Societies*; Copenhagen, Denmark.

Paolone G, Emerich DF, Bell W, Fradet T, Simonato M, Wahlberg LU (2016). Encapsulated cell therapy for epilepsy: long-term, stable and efficacious targeting of the hippocampus with GDNF. *Gordon Research Conference, Mechanisms of Epilepsy & Neural Synchronization*; Girona, Spain.

Pedrazzoli M, Losurdo M, **Paolone G**, Avesani A, Coco S, Buffelli M (2018). Glucocorticoids deeply affect spine plasticity and inflammation in an animal model of Alzheimer Disease. *Federation of European Neuroscience Societies*; Berlin, Germany.

Pedrazzoli M, Losurdo M, **Paolone G**, Medelin M, Jaupaj L, Cisterna B, Slanzi A, Malatesta M, Coco S, Buffelli M (2019). Glucocorticoid receptor modulation alters dendritic spine density and microglia activity in an animal model of Alzheimer's disease. *Society for Neuroscience*. **Abstract 354.09, selected for nanosymposium.**

DICHIARAZIONE DI VERIDICITÀ

Il contenuto del presente curriculum vitae corrisponde a verità e le dichiarazioni in esso contenute vengono rese ai sensi degli artt. 46 e 47 del D.P.R.445/2000 (dichiarazione sostitutiva di certificazione e/o sostitutiva dell'atto di notorietà).

DATI PERSONALI

Si autorizza il trattamento dei dati personali ai sensi dell'art. 13 Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".